New drugs in the treatment of gastric tumors

被引：17

作者：

Abad A. ^{[1
]}

机构：

[1] Medical Oncology Service, University Hospital Germans Trias i Pujol, Catalan Institute of Oncology (ICO), ES-08916 Badalona, Barcelona, Carretera Canyet s/n

来源：

Clinical and Translational Oncology | 2008年 / 10卷 / 5期

关键词：

Gastric cancer; Hedgehog signaling pathway; Helicobacter pylori; Target therapy;

D O I：

10.1007/s12094-008-0194-9

中图分类号：

学科分类号：

摘要：

Despite the progress in cancer therapeutics and chemotherapy development with the introduction of new drugs, advanced gastric cancer continues to have an extremely poor prognosis and with limited treatment options. The introduction of new antitarget drugs has introduced a new perspective in cancer treatment in general and gastric cancer in particular. Nevertheless, few studies have been developed with this generation of drugs. The monoclonal antibody antiepidermal growth factor receptor (EGFR) cetuximab and the antiangiogenic bevacizumab have been used in phase I and II studies with good results, which need to be confirmed in new phase III studies. The carcinogenesis of this tumor provides information regarding two transcription and signaling pathways of great interest and with therapeutic potential. Infection by Helicobacter pylori is recognized as the cause of gastric cancer development, and there are two elements that play an important role in this process: The CagA gene, whose protein is introduced in the cell by H. pylori initiates the process; and the hedgehog signaling pathway, which regulates the gastric mucosa and is very frequently activated in gastric cancer. Taking action on these agents may be a new and effective method of treating gastric cancer, and therefore must be researched. © Feseo 2008.

引用

页码：256 / 261

页数：5

共 20 条

[1]

Schwartz G.K., Shah M.A., Targeting the cell cycle: A new approach to cancer therapy, J Clin Oncol, 23, 36, pp. 9408-9421, (2005)

[2]

Pinto C., Di Fabio F., Siena S., Et al., Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study), Ann Oncol, 18, 3, pp. 510-517, (2007)

[3]

Shah M.A., Ramanathan R.K., Ilson D.H., Et al., Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, J Clin Oncol, 24, 33, pp. 5201-5206, (2006)

[4]

Dragovich T., McCoy S., Fenoglio-Preiser C.M., Et al., Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127, J Clin Oncol, 24, 30, pp. 4922-4927, (2006)

[5]

Rebischung C., Barnoud R., Stefani L., Et al., The effectiveness of trastuzumab (herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein, Gastric Cancer, 8, 4, pp. 249-252, (2005)

[6]

Kim S.Y., Kim H.P., Kim Y.J., Et al., Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin, Int J Oncol, 32, 1, pp. 89-95, (2008)

[7]

Rao S., Starling N., Benson M., Et al., Phase I study of the humanized epidermal grow factor receptor antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric adenocarcinoma, J Clin Oncol, 23, 16 S, (2005)

[8]

Uemura N., Okamoto S., Yamamoto S., Et al., Helicobacter pylori infection and the development of gastric cancer, N Eng J Med, 345, 11, pp. 784-789, (2001)

[9]

Tstsumi R., Higashi H., Higuchi M., Et al., Attenuation of Helicobacter pylori CagA-SHP-2 signaling by interaction between CagA and C-terminal Src Kinase, J Biol Chem, 278, 6, pp. 3665-3670, (2003)

[10]

Hatakeyama M., Helicobacter pylori CagA-a bacterial intruder conspiring gastric carcinogenesis, Int J Cancer, 119, pp. 1217-1223, (2006)

← 1 2 →